/
Oncology
Advanced Malignant Tumors
38
Pipeline Programs↗
43
Active Trials↗
32
Companies Involved↗
Advanced Malignant Tumors is a moderately active landscape with 38 programs across 32 companies. The most active players are SUNHO（China）BioPharmaceutical CO., Ltd., Shenyang Sunshine Pharmaceutical Co., LTD., LaNova Medicines Limited.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
SPhase 2SPhase 1LPhase 2
Phase 2JPhase 2
Phase 2
SUNHO（China）BioPharmaceutical CO., Ltd.
3 programs
Shenyang Sunshine Pharmaceutical Co., LTD.
3 programs
LaNova Medicines Limited
2 programs
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2 programs
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
1 program
Qilu Pharmaceutical Co., Ltd.
1 program
Pipeline
Programs by Phase
Preclinical
No programs
Phase 118
Phase 220
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
81%
Small molecule
29 of 36 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 36 classified programs, each share of the total. Modality classified for 100% of 38 pipeline programs.
Analysis
Trial Status
81
clinical trials
Recruiting28 · 35%
Unknown status20 · 25%
Completed15 · 19%
Not yet recruiting11 · 14%
Active, not recruiting4 · 5%
Terminated3 · 4%
Clinical Trials
Trial Activity
81 trials
A Clinical Trial Evaluating Injection of TQB6411 in Subjects With Advanced Malignant Tumors
Recruiting·CChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.·Phase 1·NCT07043751·216 enrolled
A Study of CSCJC3456 in Patients With Advanced Malignant Tumors
Recruiting·CChangshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.·Phase 1·NCT06717750·102 enrolled
Page 1 of 6
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)